Characteristics of Medicare Part D beneficiaries who reach the drug benefit threshold in both of the first two years of the Part D benefit

Medical Care

Volumn 48, Issue 3, 2010, Pages 267-272

  Bayliss, Elizabeth A ^a,b   Ellis, Jennifer L ^a   Delate, Thomas ^c   Steiner, John F ^a,b   Raebel, Marsha A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Pharmacy Department   (United States)

Author keywords

Coverage gap; Medicare Part D; Prescription insurance

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; PSYCHOTROPIC AGENT;

AGED; ARTICLE; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; EMERGENCY WARD; FALLING; FEMALE; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INCONTINENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICARE; MIGRAINE; MORBIDITY; PARKINSON DISEASE; PATIENT CARE; PNEUMONIA; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SKIN ULCER; STROKE; SYNCOPE; TEST STRIP; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICARE PART D; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 77649158928     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181ca2824     Document Type: Article

References (25)

1. The Henry J. Kaiser Family Foundation. Medicare Fact Sheet: The Medicare Prescription Drug Benefit. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2006. 7044-7104
2. Cox ER, Jernigan C, Coons S, et al. Medicare beneficiaries' management of capped prescription benefits. Med Care. 2001;39:296-301.
3. Tseng C, Brook RH, Keeler E, et al. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952-960.
4. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354:2349-2359.
5. Raebel MA, Delate T, Ellis JL, et al. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care. 2008;46:1116-1122.
6. Stuart BC. How disease burden influences medication patterns for Medicare beneficiaries: implications for policy. Issue Brief (Commonw Fund). 2008;30:1-12.
7. Daniel GW, Malone DC. Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. J Manag Care Pharm. 2007;13:142-154.
8. Piette JD, Heisler M. The relationship between older adults' knowledge of their drug coverage and medication cost problems. J Am Geriatr Soc. 2006;54:91-96.
9. Hsu J, Fung V, Price M, et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299:1929-1936.
10. Neuman P, Strollo MK, Guterman S, et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff (Millwood). 2007;26:w630-w643.
11. American Society of Consultant Pharmacists. ASCP Issue Paper: Medicare Drug Benefit Questions and Answers. Alexandria, VA: American Society of Consultant Pharmacists; 2005.
12. The Henry J. Kaiser Family Foundation. Medicare Fact Sheet: The Medicare Prescription Drug Benefit. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2007.7044-7106
13. Centers for Medicare and Medicaid Services. Medicare Part D Medication Therapy Management (MTM) Programs 2008 Fact Sheet. Baltimore, MD: Centers for Medicare and Medicaid Services;2008.
14. Touchette DR, Burns AL, Bough MA, et al. Survey of medication therapy management programs under Medicare part D. J Am Pharm Assoc (2003). 2006;46:683-691.
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-Cm and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
16. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
17. Fung V, Tager IB, Brand R, et al. The impact of generic-only drug benefits on patients' use of inhaled corticosteroids in a Medicare population with asthma. BMC Health Serv Res. 2008;18:151.
18. Hargrave E, Hoadley J, Cubansik J, et al. Medicare Part D 2008 Data Spotlight: Ten Most Common Brand-Name Drugs. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2008. 7749.
19. Hoadley J. Medicare Part D. Simplifying the program and improving the value of information for beneficiaries. Commonw Fund. 2009:Issue Brief 1118.
20. Mager DE, Cox ER. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate. Am J Manag Care. 2007;13:347-352.
21. Gilman BH, Kautter J. Consumer response to dual incentives under multitiered prescription drug formularies. Am J Manag Care. 2007;13:353-359.
22. Berkowitz SA, Gerstenblith G, Anderson GF. Medicare prescription drug coverage gap. Navigating the "doughnut hole" with patients. JAMA. 2007;297:868-870.
23. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systemic review and meta-analysis. JAMA. 2008;300:2514-2526.
24. Naessens JM, Kahn M, Shah ND, et al. Effect of premium, copayments, and health status on the choice of health plans. Med Care. 2008;46: 1033-1040.
25. Tseng C, Brook RH, Keeler E, et al. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients. JAMA. 2003; 290:222-227.